UB Paderborn / Katalog / Suche / in CDI

Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC)

Annals of oncology, 2018-10, Vol.29, p.viii718-viii719

2018

Volltextzugriff (PDF)

Atezolizumab + bevacizumab in hepatocellular carcinoma (HCC): Safety and clinical activity results from a phase Ib study

Annals of oncology, 2018-11, Vol.29, p.ix47-ix47

2018

Volltextzugriff (PDF)

Lung deposition and pharmacokinetics of nebulized cyclosporine in lung transplant patients

Journal of aerosol medicine and pulmonary drug delivery, 2014-06, Vol.27 (3), p.178

2014

Volltextzugriff (PDF)

Atezolizumab + bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma: The randomised phase III study IMbrave150

Annals of oncology, 2018-10, Vol.29, p.viii267-viii267

2018

Volltextzugriff (PDF)

IMbrave150: A randomised phase III study of atezolizumab + bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma

Annals of oncology, 2018-11, Vol.29, p.ix66-ix66

2018

Volltextzugriff (PDF)

Serum IGF-1 Scores and Clinical Outcomes in the Phase III IMbrave150 Study of Atezolizumab Plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma

Journal of hepatocellular carcinoma, 2022-01, Vol.9, p.1065-1079

2022

Volltextzugriff (PDF)

How Does Corporate Political Activity Allowed by Citizens United v. Federal Election Commission Affect Shareholder Wealth?

The Journal of law & economics, 2015-08, Vol.58 (3), p.545-559

2015

Volltextzugriff (PDF)

54O Safety outcomes by UGT1A1 status in the phase III TROPiCS-02 study of sacituzumab govitecan (SG) in HR+/HER2– metastatic breast cancer (mBC)

Annals of oncology, 2023-11, Vol.34, p.S1486-S1487

2023

Volltextzugriff (PDF)

389P Efficacy and safety analyses by prior lines of chemotherapy from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC)

Annals of oncology, 2023-10, Vol.34, p.S343-S344

2023

Volltextzugriff (PDF)

SA21 Feasibility Assessment of an Indirect Treatment Comparison (ITC) of Sacituzumab Govitecan (SG) Vs Trastuzumab Deruxtecan (T-DxD) in HR+/HER2– Metastatic Breast Cancer (mBC)

Value in health, 2023-12, Vol.26 (12), p.S545

2023

Volltextzugriff (PDF)

Does Shareholder Proxy Access Damage Share Value in Small Publicly Traded Companies?

Stanford law review, 2012-06, Vol.64 (6), p.1431-1468

2012

Volltextzugriff (PDF)

1553O Health-related quality of life (HRQoL) in the phase III TROPiCS-02 trial of sacituzumab govitecan (SG) vs chemotherapy in HR+/HER2- metastatic breast cancer (MBC)

Annals of oncology, 2022-09, Vol.33, p.S1258

2022

Volltextzugriff (PDF)

194: Inhaled Cyclosporine Is Well Tolerated in the CYCLIST Clinical Trial

The Journal of heart and lung transplantation, 2010-02, Vol.29 (2), p.S68-S68

2010

Volltextzugriff (PDF)

932P IMbrave150: Exploratory efficacy and safety results in patients with hepatocellular carcinoma without macrovascular invasion (MVI) or extrahepatic spread (EHS) treated with atezolizumab (atezo) + bevacizumab (bev) or sorafenib (sor)

Annals of oncology, 2021-09, Vol.32, p.S818-S818

2021

Volltextzugriff (PDF)

Pandora's Ballot Box, Or a Proxy with Moxie? Majority Voting, Corporate Ballot Access, and the Legend of Martin Lipton Re-Examined

The Business Lawyer, 2007-05, Vol.62 (3), p.1007-1057

Verret, J.W.

2007

Volltextzugriff (PDF)

LBA76 Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC)

Annals of oncology, 2022-09, Vol.33, p.S1386

2022

Volltextzugriff (PDF)

986P Efficacy of atezolizumab (atezo) + bevacizumab (bev) after disease progression with atezo monotherapy in patients with previously untreated, unresectable hepatocellular carcinoma (HCC)

Annals of oncology, 2020-09, Vol.31, p.S690-S690

2020

Volltextzugriff (PDF)

Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)

Annals of oncology, 2019-11, Vol.30, p.ix187

2019

Volltextzugriff (PDF)

193P Efficacy of sacituzumab govitecan versus treatment of physician’s choice in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: A meta-analysis of TROPiCS-02 and EVER-132-002 trials

ESMO open, 2024-05, Vol.9, p.103215, Article 103215

2024

Volltextzugriff (PDF)

LBA39 - Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)

Annals of oncology, 2019-10, Vol.30, p.v875-v875

2019

Volltextzugriff (PDF)

Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)

Annals of oncology, 2019-10, Vol.30, p.v875

2019

Volltextzugriff (PDF)

LBA39Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

210TiPIMbrave150: A randomised phase III study of atezolizumab + bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma

Annals of oncology, 2018-11, Vol.29 (suppl_9)

2018

Volltextzugriff (PDF)

150OAtezolizumab + bevacizumab in hepatocellular carcinoma (HCC): Safety and clinical activity results from a phase Ib study

Annals of oncology, 2018-11, Vol.29 (suppl_9)

2018

Volltextzugriff (PDF)

LBA26Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC)

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC)

Atezolizumab + bevacizumab in hepatocellular carcinoma (HCC): Safety and clinical activity results from a phase Ib study

Lung deposition and pharmacokinetics of nebulized cyclosporine in lung transplant patients

Atezolizumab + bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma: The randomised phase III study IMbrave150

IMbrave150: A randomised phase III study of atezolizumab + bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma

Serum IGF-1 Scores and Clinical Outcomes in the Phase III IMbrave150 Study of Atezolizumab Plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma

How Does Corporate Political Activity Allowed by Citizens United v. Federal Election Commission Affect Shareholder Wealth?

54O Safety outcomes by UGT1A1 status in the phase III TROPiCS-02 study of sacituzumab govitecan (SG) in HR+/HER2– metastatic breast cancer (mBC)

389P Efficacy and safety analyses by prior lines of chemotherapy from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC)

SA21 Feasibility Assessment of an Indirect Treatment Comparison (ITC) of Sacituzumab Govitecan (SG) Vs Trastuzumab Deruxtecan (T-DxD) in HR+/HER2– Metastatic Breast Cancer (mBC)

Does Shareholder Proxy Access Damage Share Value in Small Publicly Traded Companies?

1553O Health-related quality of life (HRQoL) in the phase III TROPiCS-02 trial of sacituzumab govitecan (SG) vs chemotherapy in HR+/HER2- metastatic breast cancer (MBC)

194: Inhaled Cyclosporine Is Well Tolerated in the CYCLIST Clinical Trial

932P IMbrave150: Exploratory efficacy and safety results in patients with hepatocellular carcinoma without macrovascular invasion (MVI) or extrahepatic spread (EHS) treated with atezolizumab (atezo) + bevacizumab (bev) or sorafenib (sor)

Pandora's Ballot Box, Or a Proxy with Moxie? Majority Voting, Corporate Ballot Access, and the Legend of Martin Lipton Re-Examined

LBA76 Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC)

986P Efficacy of atezolizumab (atezo) + bevacizumab (bev) after disease progression with atezo monotherapy in patients with previously untreated, unresectable hepatocellular carcinoma (HCC)

Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)

193P Efficacy of sacituzumab govitecan versus treatment of physician’s choice in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: A meta-analysis of TROPiCS-02 and EVER-132-002 trials

LBA39 - Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)

Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)

LBA39Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)

210TiPIMbrave150: A randomised phase III study of atezolizumab + bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma

150OAtezolizumab + bevacizumab in hepatocellular carcinoma (HCC): Safety and clinical activity results from a phase Ib study

LBA26Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC)

Suchergebnisse filtern